Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Coronavirus Job Retention Scheme: Updated Government and HMRC Guidance
The government announced their Coronavirus Job Retention Scheme to help pay the wages of employees not working.
Charles Russell Speechlys advises Acora on its investment round with Palatine Private Equity
Charles Russell Speechlys advised industry leading IT service provider, Acora, on its investment round with Palatine Private Equity LLP.
Charles Russell Speechlys advises AIQ Ltd on Main Market readmission and reverse takeover of AI codes
Charles Russell Speechlys has assisted AIQ Ltd on the completion of the acquisition of AI Codes and on Main Market readmission.